Evaluation of the quality of life between inpatients and outpatients receiving cancer chemotherapy in Japan

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1127-1132

  Uramoto, Hidetaka ^a   Kagami, Seiji ^a   Iwashige, Atsushi ^a   Tsukada, Junichi ^a  

^a Japan   (Japan)

Author keywords

Chemotherapy; Outpatient; QOL

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PHYSICAL CAPACITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SOCIAL ATTITUDE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INPATIENTS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; QUALITY OF LIFE;

EID: 34247094848     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Buchanan DR, O'Mara AM, Kelaghan JW and Minasian LM: Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program. J Clin Oncol 23: 591-598, 2005.
2. Gotay CC, Isaacs P and Pagano I: Quality of life in patients who survive a dire prognosis compared to control cancer survivors. Psychooncology 13: 882-892, 2004.
3. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66-72, 1999.
4. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F et al: Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23: 6865-6872, 2005.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
7. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Ame Med Assoc 290: 2149-2158, 2003.
8. Naito M, Nakayama T and Fukuhara S: Quality of life assessment and reporting in randomized controlled trials: a study of literature published from Japan. Health Qual Life Outcomes 2: 31, 2004.
9. Fukuhara S and Suzukamo Y: Manual of the SF-8, Japanese version, Institute for Health Outcomes & Process Evaluation Research, Kyoto, pp. 71-116, 2004.
10. Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K and Shimozuma K: Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8: 355-363, 1999.
11. Gralla RJ: Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist Suppl 6: 14-24, 2004.
12. Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M and Yasumoto K: Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 51: 71-77, 2006.
13. Johnson JR, Williams G and Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21: 1404-1411, 2003.
14. Chassany O, Sagnier P and Marquis P: Patient-reported outcomes: the example of health-related quality of life - a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 36: 209-238, 2002.
15. Hollen PJ, Gralla RJ, Cox C, Eberly SW and Kris MG: A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer 18: 119-136, 1997.
16. Stephens RJ, Hopwood P, Girling DJ and Machin D: Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 6: 225-236, 1997.
17. Socinski MA, Morris DE, Masters GA and Lilenbaum R: American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123: 226-243, 2003.
18. Rubenstein EB: Evaluating cost-effectiveness in outpatient management of medical complications in cancer patients. Curr Opin Oncol 10: 297-301, 1998.
19. Ando M and Saka H: Estimated number of cancer patients treated on an outpatient basis in Japan. Gan To Kagaku Ryoho 32: 647-651, 2005.
20. Uramoto H, Kagami S, Iwashige A and Tsukada J: Out-patient treatment for cancer patients at cancer chemotherapy centers in university hospitals. J UOEH 27: 359-365, 2005.
21. Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J and Aaronson NK: The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res 7: 291-300, 1998.
22. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E and Bonomi P: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12: 199-220, 1995.
23. Hollen PJ, Gralla RJ, Kris MG and Cox C: Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73: 2087-2098, 1994.
24. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B and Belin TR: Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 92: 1054-1064, 2000.